Advanced search
Publication Cover
Vascular Health and Risk Management Volume 10, 2014 - Issue
Submit an article Journal homepage
60
Views
9
CrossRef citations to date
0
Altmetric
Short Report

Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes

Matthias Blüher1 Department of Medicine, University of Leipzig, Leipzig, GermanyCorrespondence[email protected]
,
Anja Schweizer2 Novartis Pharma AG, Basel, Switzerland
,
Giovanni Bader2 Novartis Pharma AG, Basel, Switzerland
&
James E Foley3 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Pages 661-664 | Published online: 20 Nov 2014

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Marc Evans, Anja Schweizer & James E Foley. (2016) Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus. Vascular Health and Risk Management 12, pages 337-340.
Read now

Articles from other publishers (8)

Fang Zhang, Shishi Xu, Lizhi Tang, Xiaohui Pan & Nanwei Tong. (2020) Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology 11.
Crossref
Ibrahim El Ebrashy, Nabil El Kafrawy, Rana Raouf & Diana Yousry. (2020) Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study. Diabetes Research and Clinical Practice 162, pages 108042.
Crossref
James E. Foley. (2019) Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man. Frontiers in Endocrinology 10.
Crossref
Arintaya Phrommintikul, Wanwarang Wongcharoen, Sirinart Kumfu, Thidarat Jaiwongkam, Siriluck Gunaparn, Siriporn Chattipakorn & Nipon Chattipakorn. (2019) Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study . British Journal of Clinical Pharmacology 85:6, pages 1337-1347.
Crossref
Na Wang, Jin-Ping Zhang, Xiao-Yan Xing, Zhao-Jun Yang, Bo Zhang, Xin Wang & Wen-Ying Yang. (2017) Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment. Journal of Diabetes 9:8, pages 728-737.
Crossref
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt & Norman Waugh. (2017) Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technology Assessment 21:2, pages 1-218.
Crossref
L.-N. Ji, C.-Y. Pan, J.-M. Lu, H. Li, D.-L. Zhu, Q. Li, Q.-F. Li, Y.-D. Peng, H.-M. Tian, C. Yao, Z.-G. Zhao, L. Wang & B.-H. Wang. (2016) Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION). Diabetes, Obesity and Metabolism 18:8, pages 775-782.
Crossref
Bo Ahrén & James E. Foley. (2016) Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. Diabetologia 59:5, pages 907-917.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.